Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips 2021 has been a year of positive returns for major U.S. stock indexes after an impressive year of gains despite volatility in 2020. The Dow Jones is up 12%, the S&P 500 is up 13% and the lagging Nasdaq Composite i...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IHF. A list of cheap stocks. For further details see: IHF: Healthcare Dashboard For June
Innoviva ([[INVA]] +5.2%) announced an agreement with GlaxoSmithKline ([[GSK]] +1.0%) to purchase GSK’s equity stake in the company in a deal valued at $392M.Per the terms, Innoviva will buy ~32M shares representing 32% of the outstanding common stock at $12.25 apiece indicat...
Innoviva to repurchase GSK’s current 32% stake in the company for $392 million Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today announced the execution of definitive agreement to purchase of GSK’s equity stake in In...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. For further details see: IYH: Healthcare Dashboard For May
– ATTACK Phase 3 topline data readout remains on track for second half of 2021 – – Strengthened balance sheet with $20M financing – WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage ...
Clinical-stage biopharmaceutical company Entasis Therapeutics Holdings (ETTX) has completed the initial closing of an ~$7.5M stock and warrant issuance to a subsidiary of Innoviva (INVA). Upon satisfaction of certain closing conditions, Innoviva will purchase the balance of the $20M...
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has completed the initial closing of an approximat...
Biopharma company Alkermes (ALKS), which was targeted by activist investor Elliott Management last year, has reached an agreement with Sarissa Capital, giving the activist fund the right to designate a director for the company's board.The agreement follows "constructive" dialogue between...
Innoviva (INVA): Q1 GAAP EPS of $0.84.Revenue of $85.52M (+8.7% Y/Y)Shares +1.8% AH.Press Release For further details see: Innoviva reports Q1 results
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...